Investment Firm Lodge Partners Initiates Coverage of GTG with Buy Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian investment firm Lodge Partners has initiated coverage of Genetic Technologies (GTG) with a Buy rating and 12-month price target of A$.57 ($.62), citing its BrevaGen breast cancer test and its IP portfolio as potential growth drivers.

The bank began its coverage nearly a month ago, and GTG made the report available on its website today.

Lodge also had a 2011 revenue estimate on GTG of A$21.5 million ($23.5 million) and EPS of A$.002.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.